GLAXO - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.1
| Stock Code | GLAXO | Market Cap | 39,219 Cr. | Current Price | 2,315 ₹ | High / Low | 3,516 ₹ |
| Stock P/E | 38.8 | Book Value | 132 ₹ | Dividend Yield | 2.46 % | ROCE | 65.0 % |
| ROE | 48.2 % | Face Value | 10.0 ₹ | DMA 50 | 2,414 ₹ | DMA 200 | 2,533 ₹ |
| Chg in FII Hold | -0.01 % | Chg in DII Hold | -0.02 % | PAT Qtr | 275 Cr. | PAT Prev Qtr | 277 Cr. |
| RSI | 37.0 | MACD | -17.7 | Volume | 1,91,002 | Avg Vol 1Wk | 1,08,315 |
| Low price | 2,218 ₹ | High price | 3,516 ₹ | PEG Ratio | 1.96 | Debt to equity | 0.01 |
| 52w Index | 7.51 % | Qtr Profit Var | 5.69 % | EPS | 59.7 ₹ | Industry PE | 30.5 |
📊 Financials: GlaxoSmithKline Pharmaceuticals shows stable fundamentals with quarterly PAT of ₹275 Cr. versus ₹277 Cr. previously, reflecting flat profit growth. Debt-to-equity is negligible at 0.01, ensuring minimal leverage risk. ROE at 48.2% and ROCE at 65.0% are exceptional, highlighting strong capital efficiency. Cash flows remain steady, supported by consistent demand for pharmaceutical and healthcare products.
💹 Valuation: The stock trades at a P/E of 38.8, above the industry average of 30.5, suggesting a premium valuation. P/B ratio is ~17.5 (Price ₹2315 / Book Value ₹132), which is high and reflects brand strength. PEG ratio of 1.96 indicates growth-adjusted valuation is stretched. Intrinsic value analysis suggests the stock is slightly overvalued at current levels.
🏢 Business Model: Glaxo operates in the pharmaceutical and healthcare sector, focusing on prescription drugs, vaccines, and consumer health products. Its competitive advantage lies in strong brand recognition, global parent support, and regulatory approvals. The company benefits from steady demand and high entry barriers in pharma manufacturing.
📈 Entry Zone: With DMA 50 at ₹2414 and DMA 200 at ₹2533, the stock is trading below both averages, indicating weakness. RSI at 37.0 suggests oversold conditions, while MACD at -17.7 confirms bearish momentum. Accumulation near ₹2200–₹2300 offers a favorable entry zone for long-term investors.
Positive
- 🚀 Exceptional ROE (48.2%) and ROCE (65.0%).
- 💰 Strong dividend yield of 2.46% supports income investors.
- 📉 Negligible debt ensures financial stability.
- 🌍 Global parent support enhances competitive positioning.
Limitation
- ⚠️ High P/B ratio (~17.5) limits valuation comfort.
- 📉 PEG ratio of 1.96 suggests stretched growth valuation.
- 🔄 Flat profit growth (PAT ₹275 Cr. vs ₹277 Cr.).
Company Negative News
- ⚠️ No major recent negative news, though weak profit momentum is a concern.
Company Positive News
- ✅ Strong dividend payout supporting shareholder returns.
- 📈 Exceptional capital efficiency with high ROE and ROCE.
Industry
- 💊 Pharmaceutical industry benefits from global demand and regulatory-driven barriers.
- 📊 Industry P/E at 30.5 reflects optimism and growth potential.
- 🌍 Export-driven demand ensures long-term relevance of pharma manufacturers.
Conclusion
GlaxoSmithKline Pharmaceuticals demonstrates strong fundamentals with high profitability, negligible debt, and global brand strength. However, valuations are stretched on P/B and PEG, and profit growth remains flat. Entry around ₹2200–₹2300 is favorable, and long-term holding is recommended for investors seeking exposure to a premium pharmaceutical company with strong capital efficiency and dividend support.
Would you like me to extend this with a peer comparison against other pharma companies or a technical analysis focusing on chart momentum and support levels?